To the full analysis
Altimmune stock: growth
ALTAltimmune reported $41K in revenue for fiscal 2025, up 105% on the prior year, down 65.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−18.2%
per year from 2006 to 2025, per share −45.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −65.3% | −42.6% | −18.2% |
| Revenue per share | −72.9% | −68.6% | −45.2% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.85M | $1.02M | $1.53M |
| 2007 | $14.64M | −$13.59M | −$14.52M |
| 2008 | $32.91M | −$36.42M | −$13.71M |
| 2009 | $27.55M | −$32.28M | −$29.18M |
| 2010 | $20.99M | −$34.85M | −$15.24M |
| 2011 | $24.27M | −$3.8M | −$7.88M |
| 2012 | $25.18M | −$4.92M | −$2.32M |
| 2013 | $17.91M | −$11.72M | −$7.25M |
| 2014 | $10.19M | −$9.96M | −$8.57M |
| 2015 | $10.64M | −$3.44M | −$3.3M |
| 2016 | $5.23M | $193.85M | $201.48M |
| 2017 | $41.5K | −$46.43M | −$20.38M |
| 2018 | $10.33M | −$39.17M | −$10.4M |
| 2019 | $5.8M | −$20.52M | −$9.6M |
| 2020 | $8.19M | −$49.04M | −$34.65M |
| 2021 | $4.41M | −$97.09M | −$90.55M |
| 2022 | −$68K | −$84.71M | −$62.71M |
| 2023 | $426K | −$88.45M | −$75.86M |
| 2024 | $20K | −$95.06M | −$79.85M |
| 2025 | $41K | −$88.09M | −$67.55M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.